MMPSense 680 is a protease activatable fluorescent in vivo imaging agent that is activated by key matrix metalloproteinases (MMPs) including MMP-2, -3, -9 and -13. MMPSense 680 is optically silent in its unactivated state and becomes highly fluorescent following protease-mediated activation.
MMP activity is involved in many disease-related processes including cancer progression, invasion and metastasis, rheumatoid arthritis, pulmonary diseases and areas of cardiovascular disease. MMPSense 680 may be used to monitor the progression of these diseases or to evaluate the potential therapeutic efficacy of drugs targeting the underlying mechanisms involved in these diseases.
Disclaimer: For laboratory use only. This product is intended for animal research only and not for use in humans.
|Fluorescent Agent Type||Activatable|
|Optical Imaging Classification||Fluorescence Imaging|
|Product Brand Name||MMPSense|
|Quantity in a Package Amount||1.0 Units|
|Shipping Condition||Blue Ice|
|Therapeutic Area||Atherosclerosis, Arthritis, Inflammation, Oncology/Cancer|
|Unit Size||1 Vial (10 doses)|
|Wave Length||680 nm|
You have selected:
|Resource Type||File Name||File Format|
|Brochure||FMT Fluorescence Tomography in vivo Imaging Systems||PDF 1 MB|
|Brochure||In Vivo Imaging Agents Brochure||PDF 2 MB|
|Application Note||Multiplex 2D Imaging of NIR Molecular Imaging Agents on the IVIS SpectrumCT and FMT 4000||PDF 4 MB|
|Technical Note||MMPSense 680 (Data Sheet)||PDF 49 KB|
|Technical Note||MMPSense 680 (Protocol)||PDF 256 KB|
|Featured Publication Note||Tobacco-specific Carcinogen-operated Calcium Channel Promotes Lung Tumorigenesis||PDF 217 KB|
|Poster (All)||Combined efficacy & toxicity imaging following acute 5-FU treatment of HT-29 tumor xenografts||PDF 1 MB|
|Poster (All)||Non-Invasive Quantitative Tomography of Disease Progression and Therapeutic Response||PDF 581 KB|
|Citations Library||View peer reviewed publications using PerkinElmer's In Vivo Imaging Reagents||Link|
|Webinars||View our complete list of in vivo webinars available on demand||Link|